The market for Gonorrhea Diagnostics is expected to reach US$ XX Bn in 2026.
Gonorrhea is caused by the infection of the bacterium Neisseria gonorrhea, which usually affects the moist and warm areas of the body, such as the vagina, anus, urethra, throat, and eyes. It is classified as the second most common sexually transmitted disease (STD) as it has the potential to spread through unprotected sex or multiple sexual partners. Due to the high morbidity rate and imminent threat of gonorrhea being resistant to cephalosporin, it is necessary to understand the disease epidemiology of gonorrhea. As per the latest research cited in the Centers for Disease Control and Prevention’s 2016 report, the global prevalence of gonorrhea is 142.1 cases per 100,000 people. The occurrence is higher in women in comparison to men and is widely prevalent in regions such as North America, Latin America, Africa, and other developing nations of South Asia.
The World Health Organization has postulated a treatment guideline for gonorrhea in order to overcome the problem of microbial resistance, which consists of the use of antibiotics such as third-generation cephalosporins, doxycycline, azithromycin, gemifloxacin, etc. For effective diagnosis of gonorrhea, the cell culture standard test is considered the gold standard due to its inherent features such as high specificity, high sensitivity, and relatively low cost. The problems associated with the cell culture of Neisseria are the need to maintain bacterial viability during storage and transport, and approximately 24–72 hours are required before a preliminary culture test result is obtained. The nucleic acid amplification test (NAAT) has been approved by the USFDA for analyzing genital specimens only and has been beneficial in gaining positive results with very little genetic material, urine samples, and vaginal swabs. For analyzing extra-genital specimens, gonorrhea diagnosis is performed with serological tests, monoclonal antibody tests, flow cytometry, etc.
Type
Molecular diagnostic tests
Geography
Europe
Asia Pacific
Latin America
Middle East and Africa
Abbott Laboratories, Agilent Technologies, Beckman Coulter, Inc., Becton Dickinson & Company, bioMérieux, Inc., Cepheid, Inc., PerkinElmer, Inc., Pfizer, Inc., Roche Diagnostics, and Siemens AG
The market for Gonorrhea Diagnostics is expected to reach US$ XX Bn in 2026.
The Gonorrhea Diagnostics market is expected to see significant CAGR growth over the coming years,at XX%.
The report is forecasted from 2018-2026.
The base year of this report is 2017.